Latigo Biotherapeutics, Inc. (LTGO) Fair Value 2026

LTGO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-09-15, Latigo Biotherapeutics, Inc. (LTGO) trades at $23.01. QOC: 3.1/10. Value Trap Risk: 0/100 (SAFE). 0/13 models active.

Key Facts

Ticker
LTGO
Price
$23.01
Quality Score
3.1/10
Value Trap Risk
0/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 3.1/10 signals weak fundamentals

What Fair Value Does Each Model Give LTGO?

0 Intrinsic Value Models vs. Current Price ($23.01)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Latigo Biotherapeutics, Inc. (LTGO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Latigo Biotherapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About LTGO?

0 of 13 models are currently active for LTGO. See which stocks rank higher →

How Does LTGO Rank in Biotechnology?

Among 624 Biotechnology stocks, LTGO ranks #593 by Quality of Company score. CirclFi's QOC score of 3.1/10 evaluates 32 fundamental signals. A score of 3.1 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Latigo Biotherapeutics, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is LTGO a Value Trap?

CirclFi's Value Trap algorithm assigns LTGO a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Latigo Biotherapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Latigo Biotherapeutics, Inc. earns a quality score of 3.1/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LTGO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Latigo Biotherapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BRVEBraveheart Bio, Inc.QOC 3.2CLGNCollPlant Biotechnologies Ltd.QOC 3.0CLLSCellectis S.A.QOC 3.2ENLVEnlivex Ltd.QOC 3.0CMNDClearmind Medicine Inc.QOC 3.2MENSJyong Biotech Ltd.QOC 3.0CRDFCardiff Oncology, Inc.QOC 6.2ORICORIC Pharmaceuticals, Inc.QOC 5.1PEPGPepGen Inc.QOC 4.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BRVE · CLGN · CLLS · ENLV · CMND · MENS · CRDF · ORIC · PEPG · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to LTGO?

6 companies across all industries closest to LTGO’s Quality of Company score of 3.1/10.

NUCLEagle Nuclear Energy Corp.QOC 3.2KBSXFST Corp.QOC 3.1REOSReoStar Energy Corp.QOC 3.1EDTKSkillful Craftsman Education Technology LimitedQOC 3.2FBDTFirst Breach, Inc.QOC 3.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NUCL · KBSX · REOS · EDTK · FBDT · NVDA

Where Does LTGO Sit in CirclFi's Biotechnology Rankings?

LTGO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Latigo Biotherapeutics, Inc.’s Valuation?

What is Latigo Biotherapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Latigo Biotherapeutics, Inc. (LTGO). The Quality of Company score is 3.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LTGO overvalued or undervalued right now?

At $23.01, 0 of 0 active models suggest LTGO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Latigo Biotherapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.1 mean for LTGO?

Latigo Biotherapeutics, Inc.'s QOC of 3.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on LTGO?

CirclFi analyzes LTGO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is LTGO a value trap in 2026?

Latigo Biotherapeutics, Inc.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Latigo Biotherapeutics, Inc. (LTGO) a Quality of Company score of 3.1/10 across 32 fundamental signals as of 2026-09-15.” Source: circlfi.com/stock/LTGO/ · Methodology
Primary sources for this LTGO valuation
  • Financial statements: Latigo Biotherapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0002056611) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LTGO as of ; valuations recomputed .